Novel Antibiotics from Unculturable Actinomycetes

来自不可培养放线菌的新型抗生素

• 批准号: 6998676
• 负责人: Losee Lucy Ling
• 金额: $ 93.29万
• 依托单位: NOVOBIOTIC PHARMACEUTICALS, LLC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-01 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6998676
• 关键词: Actinomycetales; Bacillus anthracis; antibiotics; aquatic organism; combinatorial chemistry; drug design /synthesis /production; drug discovery /isolation; genetic strain; microorganism culture; molecular biology information system; nuclear magnetic resonance spectroscopy; soil microbiology

Novel Antibiotics from Unculturable Actinomycetes The threat of bioterrorism requires novel effective countermeasures against CDC Category A agents. The broad objective of this project is to develop novel therapeutics against these agents by accessing the largest unexplored reservoir of biological and chemical diversity on our planet, "uncultivable" microorganisms. We have developed fundamentally novel cultivation approaches that provide unique access to these microorganisms (T.Kaeberlein, K.Lewis, and S.Epstein (2002) Science 296:1127-1129). These approaches are based on growing "uncultivables" in their natural environment, and subsequent domestication in the laboratory. In this research, we focus on one of the most promising groups of microorganisms, "uncultivable" Actinomycetes. We have been using our proprietary cultivation methodology to grow, isolate, and domesticate a large collection of novel Actinomycetes from various environments, including several types of soils and aquatic sediments. Our principal objective is to screen a library of novel isolates of Actinomycetes for activity against Bacillus anthracis, followed by validation and dereplication of novel antimicrobial compounds. The end product of this project will be novel candidate molecules, which we will develop into new anti-B. anthracis antibiotics in our future work.

来自不可培养放线菌的新型抗生素 生物恐怖主义的威胁需要针对CDC A类的新的有效对策 剂.该项目的广泛目标是开发新的治疗方法，通过访问我们星球上最大的未开发的生物和化学多样性库， “不可培养的”微生物。我们已经开发了提供对这些微生物的独特途径的基本新颖的培养方法（T.Kaeberlein，K.刘易斯，and S.Epstein（2002）Science 296：1127-1129）。这些方法是基于在自然环境中培养“不可培养的”，然后在实验室中驯化。在这项研究中，我们专注于最有前途的微生物群体之一，“不可培养”的放线菌。我们一直在使用我们专有的培养方法来生长，分离和驯化大量来自各种环境的新型放线菌，包括几种类型的土壤和水生沉积物。 我们的主要目标是筛选一个新的放线菌菌株库，对炭疽芽孢杆菌的活性，然后验证和去复制的新的抗菌化合物。 这个项目的最终产品将是新的候选分子，我们将开发成新的抗B。炭疽抗生素在我们未来的工作中。